PI Global Investments
Hedge Funds

Redhawk Wealth Advisors Inc. Grows Holdings in Johnson & Johnson (NYSE:JNJ)


Redhawk Wealth Advisors Inc. grew its holdings in Johnson & Johnson (NYSE:JNJGet Rating) by 31.8% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 2,517 shares of the company’s stock after purchasing an additional 607 shares during the period. Redhawk Wealth Advisors Inc.’s holdings in Johnson & Johnson were worth $446,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also added to or reduced their stakes in the company. BlackRock Inc. increased its stake in shares of Johnson & Johnson by 2.6% during the fourth quarter. BlackRock Inc. now owns 200,021,352 shares of the company’s stock valued at $34,217,654,000 after buying an additional 4,982,885 shares during the period. State Street Corp increased its stake in shares of Johnson & Johnson by 1.8% during the fourth quarter. State Street Corp now owns 144,677,639 shares of the company’s stock valued at $24,750,004,000 after buying an additional 2,492,359 shares during the period. Geode Capital Management LLC increased its stake in shares of Johnson & Johnson by 2.5% during the fourth quarter. Geode Capital Management LLC now owns 44,405,610 shares of the company’s stock valued at $7,576,867,000 after buying an additional 1,084,834 shares during the period. Norges Bank bought a new stake in Johnson & Johnson during the fourth quarter valued at about $4,172,929,000. Finally, Legal & General Group Plc boosted its position in Johnson & Johnson by 5.8% during the fourth quarter. Legal & General Group Plc now owns 17,420,146 shares of the company’s stock valued at $2,980,062,000 after purchasing an additional 948,306 shares in the last quarter. Institutional investors and hedge funds own 68.78% of the company’s stock.

Shares of NYSE:JNJ opened at $178.28 on Monday. Johnson & Johnson has a 52-week low of $155.72 and a 52-week high of $186.69. The stock has a market cap of $469.13 billion, a price-to-earnings ratio of 24.03, a PEG ratio of 3.53 and a beta of 0.63. The company has a quick ratio of 1.14, a current ratio of 1.39 and a debt-to-equity ratio of 0.39. The business has a 50-day moving average price of $176.89 and a 200-day moving average price of $174.14.

Johnson & Johnson (NYSE:JNJGet Rating) last announced its quarterly earnings data on Tuesday, April 19th. The company reported $2.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.60 by $0.07. Johnson & Johnson had a return on equity of 36.59% and a net margin of 20.90%. The firm had revenue of $23.43 billion during the quarter, compared to analysts’ expectations of $23.62 billion. During the same period last year, the business posted $2.59 earnings per share. The company’s revenue for the quarter was up 5.0% compared to the same quarter last year. As a group, equities analysts anticipate that Johnson & Johnson will post 10.23 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, June 7th. Stockholders of record on Tuesday, May 24th were paid a $1.13 dividend. This represents a $4.52 annualized dividend and a dividend yield of 2.54%. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.06. The ex-dividend date of this dividend was Monday, May 23rd. Johnson & Johnson’s dividend payout ratio (DPR) is presently 60.92%.

A number of equities research analysts recently weighed in on JNJ shares. Sanford C. Bernstein downgraded Johnson & Johnson from an “outperform” rating to a “market perform” rating and raised their price objective for the company from $180.00 to $183.00 in a research report on Wednesday, March 16th. The Goldman Sachs Group raised their price objective on Johnson & Johnson from $163.00 to $181.00 and gave the company a “neutral” rating in a research report on Tuesday, April 12th. Credit Suisse Group raised their price objective on Johnson & Johnson from $200.00 to $205.00 and gave the company an “outperform” rating in a research report on Wednesday, April 20th. Daiwa Capital Markets began coverage on Johnson & Johnson in a report on Wednesday, June 22nd. They issued an “outperform” rating for the company. Finally, Morgan Stanley raised their price target on Johnson & Johnson from $173.00 to $174.00 and gave the stock an “equal weight” rating in a report on Friday. Four research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $190.67.

In related news, CAO Robert J. Decker sold 8,462 shares of Johnson & Johnson stock in a transaction that occurred on Thursday, May 26th. The stock was sold at an average price of $180.00, for a total transaction of $1,523,160.00. Following the completion of the transaction, the chief accounting officer now directly owns 15,473 shares in the company, valued at $2,785,140. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Kathryn E. Wengel sold 40,000 shares of Johnson & Johnson stock in a transaction that occurred on Friday, June 10th. The shares were sold at an average price of $173.00, for a total value of $6,920,000.00. Following the transaction, the executive vice president now owns 71,311 shares of the company’s stock, valued at $12,336,803. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 78,161 shares of company stock valued at $13,895,302. Company insiders own 0.35% of the company’s stock.

Johnson & Johnson Company Profile (Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company’s Consumer Health segment offers baby care products under the JOHNSON’S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Featured Stories

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)



Receive News & Ratings for Johnson & Johnson Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily email newsletter.

Source link

Related posts

10 Growth Stocks in Billionaire George Soros’ Portfolio

Miles

Directors Guild pension plan recruits Edgar Smith from USC as its first CIO

Miles

Here’s How Hedge Funds Are Speculating on Justice

Miles

Leave a Comment

SUBSCRIBE TO OUR NEWSLETTER

Get our latest downloads and information first. Complete the form below to subscribe to our weekly newsletter.

    100% secure your website.